ArticleJHLT open2026
Neonatal enterovirus myocarditis outcomes following extracorporeal membrane oxygenation (NEMO-ECMO): An ELSO registry analysis.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neonates with enterovirus myocarditis may require extracorporeal membrane oxygenation (ECMO). The contemporary prognosis and risk factors for mortality of neonates with enterovirus myocarditis supported on ECMO is unknown. Methods: Retrospective cohort study of Extracorporeal Life Support Organization (ELSO) registry patients < 28 days old supported on V-A ECMO with enterovirus myocarditis. Primary outcome was survival to discharge. Secondary outcome was transplant-free survival to discharge. Demographic and ECMO-related variables were assessed as predictors of survival and transplant-free survival to discharge. Results: 163 neonates from 2000 to 2023 required ECMO for enterovirus myocarditis. The indication for ECMO was cardiac in 136 (83.4%) and eCPR in 16 (9.8%). Median duration of ECMO was 9.3 days (IQR 5.9-15.7). Hospital survival was 50.4% overall; 64.6% in the 2018 to 2023 era. ECMO bridge to VAD resulted in hospital mortality in 80%. Transplant-free survival at discharge was 44.2%. Variables negatively associated with hospital survival in multivariable regression analysis were age ≤ 8 days (OR 0.10, 95% CI 0.04-0.28), ECMO duration > 15.7 days (OR 0.29, 95% CI 0.11-0.78), central cannulation (OR 0.24, 95% CI 0.07-0.84), hyperbilirubinaemia (OR 0.15, 95% CI 0.03-0.89) and cerebral infarction (OR 0.07, 95% CI 0.01-0.72). Conclusions: ECMO is an effective bridge to recovery in neonates with enterovirus myocarditis, with contemporary survival comparable to other neonatal indications for extracorporeal support. Risk factors including age ≤ 8 days and ECMO duration > 16 days define a high-risk cohort. Neonates bridged directly to VAD from ECMO have a dismal outcome. There is a critical need to improve outcomes in neonatal enterovirus myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.